Akari Therapeutics Partners with WuXi XDC to Advance First-in-Class RNA Splicing ADC Payload

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating p...

April 08, 2026 | Wednesday | News
Sanofi’s Lunsekimig Delivers Strong Phase 2 Wins in Asthma and CRSwNP, Expanding Promise of Dual-Target Respiratory Therapy

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES pha...

April 08, 2026 | Wednesday | News
SonoNeu Emerges from Stealth to Advance Sonogenetics as a Breakthrough Drug-Free Therapeutic Modality

Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged&r...

April 08, 2026 | Wednesday | News
Cocrystal Pharma, Inc. Secures FDA Fast Track for CDI-988, Advancing First Oral Antiviral for Norovirus

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob...

April 07, 2026 | Tuesday | News
Curanex Pharmaceuticals, Inc. Expands Pipeline to Target Cancer Cachexia, Addressing Major Oncology Supportive-Care Gap

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...

April 07, 2026 | Tuesday | News
Intelligent Bio Solutions Completes Key Clinical Study, Advances Toward FDA 510(k) Clearance for Fingerprint Drug Test

Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for ...

April 07, 2026 | Tuesday | News
BioCardia, Inc. Submits CardiAMP HF Data to FDA, Eyes Accelerated Approval Pathway for Heart Failure Therapy

BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis...

April 07, 2026 | Tuesday | News
FDA Extends EYLEA HD Dosing Interval to 20 Weeks, Advancing Long-Term Retinal Care

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...

April 07, 2026 | Tuesday | News
Cipla USA Inc. Secures U.S. FDA Approval for Generic Nintedanib Capsules

- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...

April 06, 2026 | Monday | News
OneCyte and Kemp Proteins Partner to Transform Cell Line Development

OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and...

April 06, 2026 | Monday | News
U.S.–Taiwan Biopharma Ties Deepen as PharmaEssentia Corporation Launches Puerto Rico Expansion

A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight PharmaEssentia Corporation (TWS...

April 06, 2026 | Monday | News
Canada Invests $79M in Aspect Biosystems to Fast-Track Cellular Therapies for Chronic Diseases

Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...

April 06, 2026 | Monday | News
CellCarta And Pillar Biosciences Partner To Accelerate Biomarker Driven Oncology Trials

The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...

April 03, 2026 | Friday | News
Oncotelic Therapeutics Partners with TechForce Robotics to Commercialize AI-Driven GMP Robotics Platform

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...

April 03, 2026 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close